<DOC>
	<DOCNO>NCT02968784</DOCNO>
	<brief_summary>This study intend show ExAblate™ MRgFUS safe procedure significantly postpone eliminate need patient organ confine intermediate risk prostate cancer undergo definitive treatment ( i.e. , Radical Prostatectomy Radiation therapy ) disease .</brief_summary>
	<brief_title>Focal ExAblate MR-Guided Focused Ultrasound Treatment Management Organ-Confined Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>This study evaluate proportion patient organ-confined intermediate risk prostate cancer ( OC-IRPC ) undergo focal ExAblate™ MRgFUS prostate treatment free clinically significant PCa require definitive treatment 2 year completion ExAblate™ treatment demonstrate safety focal ExAblate™ MRgFUS treatment . Clinically significant PCa require definitive treatment define pathology finding whole-gland , imaging-guided , extend mapping biopsy Gleason Score ( GS ) &gt; 7 The primary efficacy endpoint trial , measure 24 month whole-gland extend imaging-guided mapping biopsy , Response score dichotomously subject follow : - Response = 0 ( `` Failure '' ) : Positive mapping biopsy define Gleason Score &gt; 7 ( indicate definitive treatment ) part prostate gland - Response = 1 ( `` Success '' ) : Negative mapping biopsy define Gleason Score &lt; 7 . Safety ExAblate™ treatment determine evaluation incidence severity device relate complication first treatment day visit throughout entire follow-up duration . All adverse event capture record . However , safety ExAblate™ treatment define incidence severity treatment device related adverse event , grade III - V ( CTCAE version 4.03 ; 2010-06-14 ) . Secondary Effectiveness Outcomes : 1 . % patient negative 5-month follow-up biopsy result treat part prostate 2 . Treatment effect patient ' Quality Life ( QoL ) , follow validate self-reported urogenital functioning assessment instrument use follow treatment pre-specified interval . 1 . Urinary symptom - IPSS 2 . Urinary continence - ICIQ-UI-SF 3 . Sexual function - IIEF-15 3 . PSA level post-treatment PSA kinetics also assess</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Male ≥ 50 year old 2 . Life expectancy &gt; 10 year 3 . Prostate volume &lt; 60 cc 4 . PSA ≤ 20 ng/ml 5 . Histologically proven PCa imagingguided transrectal transperineal extend mapping biopsy 6 . Based imagingguided extended mapping biopsy : 1 . T1T2b ( positive focus detect single side prostate ) 2 . Gleason Score least one focus : 7 ( =3+4 4+3 ; Gleason 5 pattern ) 3 . Additional focus may find lobe , may Gleason≤7 ( 3+4 4+3 ; Gleason 5 pattern ) 4 . N0 , M0 7 . Index lesion ( Gleason 7 ) must visible MRI 8 . Maximal diameter cancerous focus 20mm , MRI 9 . Maximal tumor length contact prostate capsule 5mm 10 . No extracapsular extension 11 . No involvement seminal vesicle 12 . Patient weight &lt; 113 Kg 13 . Patient eligible epidural general anesthesia ( assessed anesthesiologist ) 14 . Patient willing able give consent attend study visit define protocol . 1 . Biopsy confirm MRI suspect lesion contralateral side prostate screen 2 . ASA status &gt; 2 3 . Any Contraindication MRI , : 3.1 . Oversize limitation avoid patient 's positioning bore MRI scanner 3.2 . Claustrophobia 3.3 . Implanted ferromagnetic material foreign object 3.4 . Known contraindication utilization MRI contrast agent ( e.g. , Gadolinium/Magnevist ) 4 . Severely abnormal coagulation ( INR &gt; 1.5 ) 5 . Patient unstable cardiovascular status include : 5.1 . Unstable angina pectoris medication 5.2 . Documented myocardial infarction within 90 day prior enrolment 5.3 . Congestive heart failure NYHA class IV 5.4 . Unstable arrhythmia status , already antiarrhythmic drug 5.5 . Severe hypertension ( diastolic BP &gt; 100 medication ) 5.6 . Severe cerebrovascular disease ( multiple CVA CVA within last 6 month ) 6 . History prostatectomy , radiation therapy pelvis malignancy , brachytherapy , Cryotherapy , USguided HIFU , orchiectomy , prostate photodynamic therapy , prostate cancerspecific chemotherapy . 7 . Patients apical index lesion treat tumor free margin preserve least 10mm urethral sphincter . 8 . Patient androgen deprivation therapy ( ADT ) , alpha reductase inhibitor , and/or hormonal treatment within past 6 month 9 . Any rectal disease , pathology , anomaly , injury , previous treatment , scar could change acoustic property rectal wall , might prevent safe probe insertion ( e.g. , inflammatory bowel disease , fistula , stenosis , fibrosis , symptomatic hemorrhoid ) 10 . History invasive malignancy basal squamous skin cancer last 5 year 11 . Existing urethral bladder neck contracture/stricture 12 . Patient baseline symptom incontinence , define score &gt; 3 ICIQSF Questionnaire 13 . Active UTI 14 . Prostatitis NIH category I , II III 15 . Implant near ( &lt; 1cm ) prostate 16 . Inability avoid injury urethral sphincter bladder neck treatment due vicinity detect cancer . 17 . Calcification 2 mm large diameter neighbor rectal wall ( distance le 5 mm rectal wall ) potentially interfere acoustic beam path . 18 . Interest future fertility 19 . Current participation another clinical investigation medical device drug participate study within 30 day prior study enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>MRgFUS</keyword>
	<keyword>ExAblate</keyword>
	<keyword>Focused Ultrasound</keyword>
</DOC>